“Emerging data for PT150 and PT157 show promising results in ex-plant models for pancreatic cancer, glioblastoma and treatment-resistant prostate cancer”

ASCO20 Scientific Program Abstract


A new modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2


A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2

PT Oncology Drug Platform

Glucocorticoid & Androgen Receptor Antagonist/Modulators for Oncology

National Cancer Institute Study Results on Multiple Cancers

PT150 Oncology Studies

PT157 Oncology Studies​

PT162 Oncology Studies

PT167 Oncology Studies

Palisades Therapeutics new class of Antibiotics granted patent

The Palisades Therapeutics’ Potentiating Agents as broad-spectrum adjunctive therapeutics (Recently patented proprietary compounds as a platform).